What are you searching for?

Sign in
Breaking News, Promotions & Moves

Clinigen Appoints New CFO

Nick Keher joins from Royal Bank of Canada (RBC) where he was a managing director and head of RBC’s European Healthcare equity research team

Clinigen Group has appointed Nick Keher as Group chief financial officer effective March 19, 2019. He will replace Martin Abell, who has resigned effective March 31, 2019.

Nick joins from Royal Bank of Canada (RBC) where he was a managing director and head of RBC’s European Healthcare equity research team. He has covered the European healthcare space for over eight years at both RBC and Investec.

Nick started his career at Lloyd’s Pharmacy, registering as a pharmacist before joining GlaxoSmithKline (GSK). At GSK Nick worked within the Group’s R&D, UK Commercial Operations and Global Manufacturing & Supply Strategy finance teams where he trained as an accountant. 

 
Peter Allen, chairman of Clinigen, said, “On behalf of the Board and everyone at Clinigen, I would like to thank Martin for his substantial contribution over the last three and a half years. During which time Clinigen has undergone a period of rapid change and development including the acquisitions and integration of Idis, Link, Quantum and CSM, plus a number of products. We wish him every success for the future.”

Shaun Chilton, Group chief executive officer of Clinigen, said, “Nick brings considerable pharmacy and pharmaceutical experience as well as financial expertise, both as an accountant and from working in the financial markets. He has a deep knowledge and insight of our business through his research and analysis of Clinigen since its IPO in 2012. He will be a key addition to the executive management team.”

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters